|Bid||2.5900 x 4000|
|Ask||2.6000 x 1400|
|Day's Range||2.5800 - 2.7350|
|52 Week Range||2.5500 - 7.2700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.72|
- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating patients at sixth dose cohort of 210 mg/m2 - SAN DIEGO and TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today an
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...